Head-To-Head Review: Kirin (KNBWY) & Its Peers

Kirin (OTCMKTS: KNBWY) is one of 54 public companies in the “BEVERAGES” industry, but how does it contrast to its competitors? We will compare Kirin to similar businesses based on the strength of its analyst recommendations, risk, institutional ownership, profitability, valuation, dividends and earnings.

Analyst Recommendations

How to Become a New Pot Stock Millionaire

This is a summary of recent recommendations for Kirin and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kirin 0 0 0 0 N/A
Kirin Competitors 309 1438 1690 64 2.43

As a group, “BEVERAGES” companies have a potential upside of 11.09%. Given Kirin’s competitors higher probable upside, analysts clearly believe Kirin has less favorable growth aspects than its competitors.

Valuation & Earnings

This table compares Kirin and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Kirin $16.62 billion $2.16 billion 16.92
Kirin Competitors $7.33 billion $719.00 million -2.01

Kirin has higher revenue and earnings than its competitors. Kirin is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Kirin and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Kirin 8.10% 15.21% 6.97%
Kirin Competitors -20.05% -50.01% -7.82%

Insider and Institutional Ownership

0.2% of Kirin shares are held by institutional investors. Comparatively, 30.8% of shares of all “BEVERAGES” companies are held by institutional investors. 20.7% of shares of all “BEVERAGES” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Kirin has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Comparatively, Kirin’s competitors have a beta of 0.57, meaning that their average stock price is 43% less volatile than the S&P 500.

Summary

Kirin beats its competitors on 6 of the 10 factors compared.

Kirin Company Profile

Kirin Holdings Company, Limited is a holding company. The Company is engaged in alcohol beverages, non-alcohol beverages, and pharmaceuticals and bio-chemicals businesses. The Company’s segments include Integrated Beverages, Pharmaceuticals and Bio-chemicals, and Others. Its Others segment includes food business, such as dairy products, and others. Its businesses comprise Japan Integrated Beverages, Overseas Integrated Beverages, and Pharmaceuticals and Bio-chemicals. The Japan Integrated Beverages business conducts manufacturing and sales of alcoholic beverages and non-alcoholic beverages in Japan. The Overseas Integrated Beverages business includes Lion Nathan Limited (Lion), Schincariol Participacoes e Representacoes S.A. (Brasil Kirin) and Myanmar Brewery Limited. The Pharmaceuticals and Bio-chemicals business includes Kyowa Hakko Kirin Co., Ltd., ProStrakan Group plc and Kyowa Hakko Bio Co., Ltd.

Receive News & Ratings for Kirin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kirin and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

KeyCorp Reiterates Overweight Rating for Lam Research
KeyCorp Reiterates Overweight Rating for Lam Research
Zacks Investment Research Upgrades Luxoft  to “Hold”
Zacks Investment Research Upgrades Luxoft to “Hold”
Vincent A. Miller Sells 3,283 Shares of Foundation Medicine  Stock
Vincent A. Miller Sells 3,283 Shares of Foundation Medicine Stock
Thomas Caldecot Chubb III Sells 3,500 Shares of Oxford Industries  Stock
Thomas Caldecot Chubb III Sells 3,500 Shares of Oxford Industries Stock
FactSet  Director Sells $296,325.00 in Stock
FactSet Director Sells $296,325.00 in Stock
Roth Capital Reiterates “$6.00” Price Target for Lorus Therapeutics
Roth Capital Reiterates “$6.00” Price Target for Lorus Therapeutics


© 2006-2018 Ticker Report. Google+.